Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | ARID1A loss |
Gene Variant Detail | |
Relevant Treatment Approaches | EZH2 inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ARID1A loss | Her2-receptor positive breast cancer | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896). | 27172896 | |
ARID1A loss | Her2-receptor positive breast cancer | resistant | AZD8055 | Preclinical - Cell culture | Actionable | In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896). | 27172896 | |
ARID1A loss | breast cancer | sensitive | AZD8055 + MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cells with loss of ARID1A demonstrated restored sensitivity to AZD8055 when additionally treated with MK2206 in culture (PMID: 27172896). | 27172896 | |
ARID1A loss | ovarian cancer | predicted - sensitive | unspecified PD-L1 antibody | Preclinical | Actionable | In a preclinical study, an ARID1A-deficient orthotopic ovarian cancer mouse model treated with a PD-L1 antibody demonstrated improved survival and greater decreased tumor volume compared to those treated with control (PMID: 29736026). | 29736026 | |
ARID1A loss | colon cancer | predicted - sensitive | unspecified PD-L1 antibody | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026). | 29736026 | |
ARID1A loss | ovarian clear cell carcinoma | predicted - sensitive | JQ1 | Preclinical - Cell culture | Actionable | In a preclinical study, knockout of ARID1A in ovarian clear cell carcinoma cell lines resulted in increased sensitivity to growth inhibition by JQ1 compared to cells with wild-type ARID1A in culture (PMID: 29760405). | 29760405 | |
ARID1A loss | colorectal cancer | sensitive | Berzosertib | Preclinical - Cell culture | Actionable | In a preclinical study, Berzosertib (VX-970) inhibited viability of a colorectal cancer cell line harboring ARID1A loss in culture (PMID: 29038346). | 29038346 |